Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2009-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.108.146332PMID 19056933PMCID PMC2646805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism

  2008influential reference
• Feed‐forward excitation of striatal neuron activity by frontal cortical activation of nitric oxide signaling in vivo

  2008influential reference
• Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons

  2008influential reference
• Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

  2008influential reference
• Preclinical characterization of selective PDE 10 A inhibitors : A new therapeutic approach to the treatment of schizophrenia

  2008influential reference
• Increased social interaction in mice deficient of the striatal medium spiny neuron‐specific phosphodiesterase 10A2

  2008influential reference
• Dichotomous Anatomical Properties of Adult Striatal Medium Spiny Neurons

  2008cited by this paper
• Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum

  2008influential reference
• Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

  2007influential reference
• Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS‐dependent mechanism

  2007influential reference
• Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

  2007cited by this paper
• Circuits and circuit disorders of the basal ganglia.

  2007cited by this paper
• D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons.

  2007cited by this paper
• Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

  2006influential reference
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species

  2006cited by this paper
• Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

  2006influential reference
• Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

  2006cited by this paper
• Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species

  2006cited by this paper
• Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

  2006influential reference
• Phosphodiesterases in the CNS: targets for drug development

  2006influential reference
• Feedforward Inhibition of Projection Neurons by Fast-Spiking GABA Interneurons in the Rat Striatum In Vivo

  2005influential reference
• Neural systems of reinforcement for drug addiction: from actions to habits to compulsion

  2005cited by this paper
• The Nitric Oxide-Guanylyl Cyclase Signaling Pathway Modulates Membrane Activity States and Electrophysiological Properties of Striatal Medium Spiny Neurons Recorded In Vivo

  2004influential reference
• Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats

  2004influential reference
• How antipsychotics become anti-"psychotic"--from dopamine to salience to psychosis.

  2004cited by this paper
• Subcellular Localization of Cyclic Nucleotide Phosphodiesterase Type 10A Variants, and Alteration of the Localization by cAMP-dependent Protein Kinase-dependent Phosphorylation*

  2004cited by this paper
• Genes, dopamine and cortical signal-to-noise ratio in schizophrenia.

  2004cited by this paper
• The Basal Ganglia

  2004influential reference
• Does an imbalance between the dorsal and ventral striatopallidal systems play a role in Tourette's syndrome? A neuronal circuit approach.

  2003cited by this paper
• Immunohistochemical localization of PDE10A in the rat brain.

  2003influential reference
• The neurobiology of slow synaptic transmission.

  2001cited by this paper
• Synaptic organisation of the basal ganglia

  2000cited by this paper
• Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity

  2000cited by this paper
• The basal ganglia.

  2000cited by this paper
• Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A.

  1999cited by this paper
• Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

  1999cited by this paper
• Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase.

  1999cited by this paper
• A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation

  1998cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms

  1995influential reference
• GABAA receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons

  1995influential reference
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference

• AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE

  2026cites this paper
• Molecular signatures and emerging therapeutic targets in schizophrenia: A biomarker-centric perspective in psychiatric disorders.

  2025cites this paper
• Steady-state neuron-predominant LINE-1 encoded ORF1p protein and LINE-1 RNA increase with aging in the mouse and human brain

  2025cites this paper
• A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders

  2024cites this paper
• Structural insight into the lead identification of a dual inhibitor of PDE1B and PDE10A: Integrating pharmacophore-based virtual screening, molecular docking, and structure-activity-relationship approaches

  2024cites this paper
• Preclinical Evaluation of MK-8189: A Novel Phosphodiesterase 10A Inhibitor for the Treatment of Schizophrenia.

  2024cites this paper
• Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy

  2023cites this paper
• Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

  2023cites this paper
• New Dual PDE1B and PDE10A Inhibitors Identi�ed via Ligand-Based Pharmacophore Modelling and Virtual Screening

  2023cites this paper
• Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention

  2022cites this paper
• Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration.

  2022cites this paper
• Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum

  2022cites this paper
• Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia

  2022influential citation
• Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia

  2021influential citation
• PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?

  2021influential citation
• Physical activity and sedentary behavior; mechanistic insights and role in disease prevention

  2021cites this paper
• Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease

  2021cites this paper
• Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.

  2021cites this paper
• Pivotal role of phosphodiesterase 10A in the integration of dopamine signals in mice striatal D1 and D2 medium‐sized spiny neurones

  2021cites this paper
• Cellular context shapes cyclic nucleotide signaling in neurons through multiple levels of integration.

  2021cites this paper
• Ligands of the Neuropeptide Y Y2 Receptors as a Potential Multitarget Therapeutic Approach for the Protection of the Neurovascular Unit Against Acute Ischemia/Reperfusion: View from the Perspective of the Laboratory Bench

  2021cites this paper
• Pivotal role of PDE10A in the integration of dopamine signals in mice striatal D1 and D2 medium-sized spiny neurones

  2021cites this paper
• Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure

  2020cites this paper
• Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington’s Disease

  2020cites this paper
• Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression.

  2019cites this paper
• Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study

  2019cites this paper
• A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia.

  2019cites this paper
• PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.

  2019cites this paper
• Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.

  2019cites this paper
• Phosphodiesterase 10 A levels are related to striatal function in schizophrenia : a combined positron emission tomography and functional magnetic resonance imaging study

  2019cites this paper
• Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease

  2019influential citation
• Chapter 2 Current Understanding of PDE 10 A in the Modulation of Basal Ganglia Circuitry

  2018cites this paper
• In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

  2018cites this paper
• Huntington's disease: Current and future therapeutic prospects

  2018cites this paper
• Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease

  2018cites this paper
• Postsynaptic movement disorders: clinical phenotypes, genotypes, and disease mechanisms

  2018cites this paper
• Therapy development in Huntington disease: From current strategies to emerging opportunities

  2018cites this paper
• Pathobiology of Neuroinflammation and Basal Ganglia Circuitry in Parkinson's Disease

  2017influential citation
• Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.

  2017cites this paper
• Targeting phosphodiesterase type 4 for improving cognitive fronto-striatal functioning: a translational approach

  2017cites this paper
• Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.

  2017cites this paper
• PDE Inhibitors for the Treatment of Schizophrenia.

  2017cites this paper
• Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.

  2017cites this paper
• Role of Phosphodiesterases in Huntington's Disease.

  2017cites this paper
• Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram

  2017influential citation
• Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

  2017cites this paper
• Ibudilast: a non‑selective phosphodiesterase inhibitor in brain disorders.

  2017cites this paper
• Comparison between [18F]fluorination and [18F]fluoroethylation reactions for the synthesis of the PDE10A PET radiotracer [18F]MNI-659.

  2017cites this paper
• TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington’s Disease

  2017influential citation
• Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia

  2017cites this paper
• Phosphodiesterases: CNS Functions and Diseases

  2017cites this paper
• Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

  2017cites this paper
• Patterns of age related changes for phosphodiesterase type‐10A in comparison with dopamine D2/3 receptors and sub‐cortical volumes in the human basal ganglia: A PET study with 18F‐MNI‐659 and 11C‐raclopride with correction for partial volume effect

  2017cites this paper
• Huntington´s disease and the interaction between Ca2+ and cAMP signaling pathways

  2017cites this paper
• Neurophysiological Approaches for In Vivo Neuropharmacology

  2017cites this paper
• Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF

  2016cites this paper
• Soluble Guanylate Cyclase Modulators and Inhibitors for Neurological Disorders

  2016cites this paper
• Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.

  2016cites this paper
• Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [11C]MK-8193

  2016cites this paper
• Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications

  2016cites this paper
• [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP

  2016cites this paper
• Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

  2016influential citation
• Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.

  2016influential citation
• Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

  2016cites this paper
• A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

  2016cites this paper
• Working memory training triggers delayed chromatin remodeling in the mouse corticostriatothalamic circuit.

  2015cites this paper
• Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-321,2,3

  2015cites this paper
• Facilitation of Corticostriatal Transmission following Pharmacological Inhibition of Striatal Phosphodiesterase 10A: Role of Nitric Oxide-Soluble Guanylyl Cyclase-cGMP Signaling Pathways

  2015influential citation
• Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.

  2015cites this paper
• The Role of Dopamine and Dopaminergic Pathways in Dystonia: Insights from Neuroimaging

  2015cites this paper
• The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.

  2015cites this paper
• Therapeutic Strategies for Huntington's Disease.

  2015cites this paper
• Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012.

  2015cites this paper
• Altered PDE 10 A expression detectable early before symptomatic onset in Huntington ’ s disease

  2015cites this paper
• Huntington disease

  2015cites this paper
• Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.

  2015cites this paper
• Phosphodiesterase regulation of alcohol drinking in rodents.

  2015cites this paper
• Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?

  2014cites this paper
• The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington’s Disease

  2014cites this paper
• The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia

  2014cites this paper
• Phosphodiesterase 10 A Regulates Alcohol and Saccharin Self-Administration in Rats

  2014cites this paper
• In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654

  2014cites this paper
• Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal

  2014influential citation
• Targets for future clinical trials in Huntington's disease: What's in the pipeline?

  2014cites this paper
• PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways

  2014cites this paper
• Role of Cyclic Nucleotide Signaling and Phosphodiesterase Activation In The Modulation of Electrophysiological Activity of Central Neurons

  2014cites this paper
• Inhibition of Cyclic Nucleotide Phosphodiesterases to Regulate Memory

  2014cites this paper
• The Role of Phosphodiesterases in Dopamine Systems governing Motivated Behavior

  2014cites this paper
• Molecular And Cellular Understanding of PDE10A: A Dual‐Substrate Phosphodiesterase with Therapeutic Potential to Modulate Basal Ganglia Function

  2014cites this paper
• Phosphodiesterases and Cyclic Nucleotide Signaling In The CNS

  2014cites this paper
• Huntington’s Disease: Molecular Pathogenesis and New Therapeutic Perspectives

  2014cites this paper
• Phosphodiesterases as therapeutic targets for Huntington's disease.

  2014cites this paper
• Emerging biology of PDE10A.

  2014cites this paper
• Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

  2014cites this paper
• Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.

  2014influential citation
• Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis)

  2014cites this paper
• Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability.

  2014cites this paper
• The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

  2013influential citation
• A Novel Transgenic Rat Model for Spinocerebellar Ataxia Type 17 Recapitulates Neuropathological Changes and Supplies In Vivo Imaging Biomarkers

  2013cites this paper
• Can PDE inhibition improve cognition? : Translational insights

  2013cites this paper